Logo

NEWSBRIEF: Pharsight Inks Deal to Supply Aventis with Software and Support

Apr 30, 2002

SAN FRANCISCO, April 30 - Pharsight said today that it will supply software and support to Aventis Pharma for clinical development of four of the pharmaceutical company's drug candidates.

 

The multi-year deal caps a one year proof-of-product period where Pharsight applied modeling and simulation to an Aventis project, Pharsight said.

 

Aventis' software integrates its computer-based modeling of scientific, clinical, commercial, and financial information about a drug candidate to create models and simulations to help steer drug development.

 

Details of the agreement were not disclosed.

 

Pharsight said this was its largest customer deal to date.

 

For more information, click here.

Breaking News
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.